Globus Medical (GMED) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed Globus Medical (GMED) over the past year, gaining 27.0% versus a gain of 24.3%. Over five years, PEN leads with a +18.2% price change compared with -3.5% for GMED. Penumbra is the larger company by market cap ($12.51 billion vs $9.85 billion), about 1.3 times the size.
On valuation, Globus Medical trades at a lower forward P/E (13.6x vs 51.8x for Penumbra). Globus Medical converts more of its revenue into profit, with a net margin of 18.3% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | PEN |
|---|---|---|
| Share price | $73.33 | $317.52 |
| Market cap | $9.85B | $12.51B |
| 1-day change | -0.57% | +0.37% |
| YTD return | -15.53% | +1.75% |
| 1-year return | +24.35% | +27.03% |
| 5-year return | -3.51% | +18.15% |
| P/E ratio (TTM) | 18.80 | 78.01 |
| Forward P/E | 13.58 | 51.78 |
| EPS (TTM) | $3.90 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | $1.40B |
| Revenue growth (YoY) | +16.65% | +17.50% |
| Net income (latest FY) | $537.87M | $177.69M |
| Gross margin | 67.41% | 67.14% |
| Operating margin | 16.33% | 13.48% |
| Net margin | 18.30% | 12.66% |
| 52-week high | $101.40 | $362.41 |
| 52-week low | $56.50 | $221.26 |
| Distance from 52-week high | -27.68% | -12.39% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +37.62% | +13.88% |
| Average volume | 1.51M | 348.57K |
| Shares outstanding | 111.83M | 39.39M |
| Employees | 6,000 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra trades at a higher earnings multiple (78.0x vs 18.8x trailing P/E).
- Globus Medical is more profitable, keeping 18.3 cents of every revenue dollar as net income versus 12.7 cents for Penumbra.
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
GMED vs PEN FAQ
Which is bigger, Globus Medical or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.51B compared with $9.85B for Globus Medical (GMED).
Which stock has performed better over the past year, GMED or PEN?
PEN returned +27.03% over the past 12 months, compared with +24.35% for GMED (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or PEN?
GMED has the lower trailing P/E at 18.8, versus 78.0 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Globus Medical and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.